A chrono-target chemotherapy treatment model for lung cancer treatment

Therapeutic Delivery

Volumn 4, Issue 1, 2013, Pages 5-8

  Zarogoulidis, Paul ^a   Trakada, Georgia ^b   Zarogoulidis, Konstantinos ^c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

chemotherapeutic agent; circadian rhythm

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; CORTICOSTEROID; CYTOTOXIC AGENT; DEXMETHYLPHENIDATE; DOCETAXEL; DONEPEZIL; DOXORUBICIN; EPIRUBICIN; ERYTHROPOIETIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; MELATONIN; METHOTREXATE; MODAFINIL; OXALIPLATIN; PACLITAXEL; VINBLASTINE;

ACUPUNCTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MODEL; CANCER RADIOTHERAPY; CHRONOTHERAPY; CIRCADIAN RHYTHM; COLORECTAL CANCER; DEPRESSION; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TARGETING; HUMAN; LEUKOPENIA; LIGHT DARK CYCLE; LUNG CANCER; NONHUMAN; PHOTOTHERAPY; POLYSOMNOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; REGULATORY MECHANISM; REVIEW; SLEEP DISORDER; SLEEP QUALITY; SLEEP WAKING CYCLE; SYMPTOM; TREATMENT RESPONSE;

EID: 84871553894     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.137     Document Type: Review

References (20)

1. Sissung TM, English BC, Venzon D, Figg WD, Deeken JF. Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. Pharmacogenomics 11(1), 89-103 (2010).
2. Zarogoulidis P, Chatzaki E, Porpodis K et al. Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int. J. Nanomed. 7, 1551-1572 (2012).
3. Aschoff J. Circadian rhythms in man. Science 148(3676), 1427-1432 (1965).
4. Souetre E, Salvati E, Belugou JL et al. Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. Psychiatry Res. 28(3), 263-278 (1989).
5. Miaskowski C, Lee K, Dunn L et al. Sleep-wake circadian activity rhythm parameters and fatigue in oncology patients before the initiation of radiation therapy. Cancer Nurs. 34(4), 255-268 (2011).
6. Gekakis N, Staknis D, Nguyen HB et al. Role of the CLOCK protein in the mammalian circadian mechanism. Science 280(5369), 1564-1569 (1998).
7. Zarogoulidis P, Perantoni SP, Archontogeorgis E et al. Subjective sleep quality in lung cancer patients before and after chemotherapy. Thoracic Cancer doi:10. 1111/j. 1759-7714. 2012. 00156. x (2012) (Epub ahead of print).
8. Jean-Louis G, Von Gizycki H, Zizi F et al. Determination of sleep and wakefulness with the actigraph data analysis software (ADAS). Sleep 19(9), 739-743 (1996).
9. Mormont MC, Waterhouse J. Contribution of the rest-activity circadian rhythm to quality of life in cancer patients. Chronobiol. Int. 19(1), 313-323 (2002).
10. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl Cancer Inst. 85(5), 365-376 (1993).
11. Okyar A, Piccolo E, Ahowesso C et al. Strain-and sex-dependent circadian changes in abcc2 transporter expression: implications for irinotecan chronotolerance in mouse ileum. PLoS One 6(6), e20393 (2011).
12. Ohdo S, Koyanagi S, Matsunaga N. Chronopharmacological strategies: intra-and inter-individual variability of molecular clock. Adv. Drug Deliv. Rev. 62(9-10), 885-897 (2010).
13. Wang F, Weaver VM, Petersen OW et al. Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc. Natl Acad. Sci. USA 95(25), 14821-14826 (1998).
14. Zhang H, Lee MY, Hogg MG, Dordick JS, Sharfstein ST. Gene delivery in three-dimensional cell cultures by superparamagnetic nanoparticles. ACS Nano 4(8), 4733-4743 (2010).
15. Bouchahda M, Adam R, Giacchetti S et al. Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. Cancer 115(21), 4990-4999 (2009).
16. Innominato PF, Focan C, Gorlia T et al. Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res. 69(11), 4700-4707 (2009).
17. Li XM, Delaunay F, Dulong S et al. Cancer inhibition through circadian reprogramming of tumor transcriptome with meal timing. Cancer Res. 70(8), 3351-3360 (2010).
18. Sato S, Kigawa J, Irie T et al. Timing of G-CSF administration based on the circadian rhythm in patients with ovarian cancer. Am. J. Clin. Oncol. 25(3), 289-290 (2002).
19. Bernard S, Cajavec Bernard B, Levi F, Herzel H. Tumor growth rate determines the timing of optimal chronomodulated treatment schedules. PLoS Comput. Biol. 6(3), e1000712 (2010).
20. Ancoli-Israel S, Rissling M, Neikrug A et al. Light treatment prevents fatigue in women undergoing chemotherapy for breast cancer. Support Care Cancer 20(6), 1211-1219 (2012).